SubtleHD™ Gains Health Canada Approval to Support MRI Efficiency Improvements
MENLO PARK, Calif., May 14, 2025 /PRNewswire/ -- Subtle Medical, a global leader in AI-powered medical imaging enhancement, today announced that SubtleHD™ has received Health Canada approval, officially expanding access to its cutting-edge MRI image enhancement software to healthcare providers across Canada. SubtleHD is designed to dramatically reduce MRI scan times, with some sequences up to 80% faster, improve image quality, and enhance radiology workflows—all without the need for new hardware.
This clearance comes at a critical time for Canada's healthcare system. Wait times for medical imaging in the country are among the longest in the developed world. According to the Canadian Association of Radiologists, MRI wait times can stretch beyond 3 to 6 months in some provinces【¹】. In Ontario alone, more than 80% of patients wait longer than the recommended 28 days for an MRI scan【²】, often delaying diagnosis and treatment for serious conditions, including cancer, neurological disease, and musculoskeletal injuries.
SubtleHD™ will provide Canadian hospitals and imaging centers with:
SubtleHD™ is part of Subtle-ELITE™, an industry-first MRI enhancement package that also includes SubtleSYNTH™ and SubtleALIGN™—all designed to dramatically improve image quality, speed, and workflow automation. While SubtleSYNTH and SubtleALIGN are currently pending, SubtleHD™ is now commercially available in Canada as a standalone solution. Once approved, all three products will be offered together as a powerful, integrated AI package for MRI providers.
'Health Canada's clearance of SubtleHD™ is a vital milestone for improving the accessibility and quality of MRI across the country,' said Josh Gurewitz, Chief Commercial Officer at Subtle Medical. 'With this approval, healthcare providers in Canada can immediately begin using our AI to expand imaging capacity, reduce burnout, and deliver faster diagnoses for patients—without needing to buy a new scanner.'
Canadian imaging leaders have repeatedly emphasized the need for innovative solutions that can scale quickly. SubtleHD™ answers that call by empowering radiology departments to do more with less: more patients, better image quality, and greater efficiency from the same resources.
About Subtle Medical
Subtle Medical is a leading provider of AI-powered imaging solutions, optimizing scan efficiency and image quality across radiology. Recognized as a CB Insights GenAI 50 company and a two-time CB Insights Top AI 100 and Digital Health 150 company, Subtle Medical is committed to driving innovation in medical imaging. Deployed globally across 900+ scanners worldwide, Subtle Medical's solutions help imaging centers and hospitals improve workflow efficiency, increase scanner sustainability, and elevate patient care. Learn more and request a demo at www.subtlemedical.com.
Media Contact:
Anna Menyhart-Borroni
Head of Global Marketing
[email protected]
Sources for reference:
Canadian Association of Radiologists, 2024 Wait Time Report
Ontario Health Quality Report, 'Measuring Wait Times for Diagnostic Imaging' 2023
View original content to download multimedia: https://www.prnewswire.com/news-releases/subtlehd-gains-health-canada-approval-to-support-mri-efficiency-improvements-302454640.html
SOURCE Subtle Medical, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
5 hours ago
- CNBC
Northern Star Resources on Agnico Eagle acquisition rumors: 'Not surprising' as many miners need M&A
Stuart Tonkin, Managing Director & CEO of Northern Star Resources, discusses the gold miner's FY25 results and decision to drop its hedging policy to capitalize on increasing gold prices. He also comments on the rumors of a possible acquisition by Canadian-based gold producer Agnico Eagle.
Yahoo
5 hours ago
- Yahoo
Air Canada Gives Major Update as Government Moves to End Strike
The Air Canada strike is affecting approximately 100,000 travelers, as it is Canada's largest airline. So the decision on Aug. 16 by flight attendants to walk off the job is of great concern to Canada's government. Now the Canadian government is seeking binding arbitration to force the flight attendants back to work, and Air Canada has given a major update about when the airline might begin serving passengers again. Air Canada Says It Could Take a Week to Restart Operations After the Strike Ends According to Reuters, Canada's Jobs Minister Patty Hajdu told reporters on Aug. 16 that "it may take 24 to 48 hours" for the Canada Industrial Relations Board to "impose binding arbitration on both sides and order an immediate end to the strike." That's action the government is seeking due to the economic impact of the strike. Air Canada has provided a timeline for when operations could restart. According to Reuters, the Canadian airline says "restarting operations after a strike would take a week to complete." That's not good news for passengers who have had to scramble to adjust their travel plans. Mark Nasr, chief operations officer at Air Canada, told Reuters that the airline has 250 aircraft flying to more than 65 countries. "It's simply not the kind of system that we can start or stop at the push of a button," Nasr said, according to the wire service. The flight attendants' union is seeking better wages and is concerned about unpaid work, according to BBC. Air Canada Cancelled Hundreds of Flights So Far Air Canada cancelled 597 flights on Aug. 16, according to FlightAware. "Strike action by CUPE, the union representing 10,000 flight attendants at Air Canada and Air Canada Rouge, began Saturday, August 16 at 01:00 ET," Air Canada wrote in a statement on its website. The airline has a page with details about how to seek a refund. Related: Air Canada Strike Could Affect 27,000 U.S. Passengers Per Day Air Canada Gives Major Update as Government Moves to End Strike first appeared on Men's Journal on Aug 17, 2025
Yahoo
6 hours ago
- Yahoo
Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment
Merck recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial promise to their oncology pipeline. Over the last quarter, Merck's shares increased by 4.44%, aligning with the broader market's upward trend, exemplified by the S&P 500 and Nasdaq Composite hitting all-time highs. While the company's advancements in KEYTRUDA applications and Health Canada's approval for cervical cancer treatment enhancement could have contributed positively, general market optimism associated with recent stability in inflation and expected Federal Reserve interest rate cuts likely added further weight. We've identified 1 possible red flag for Merck that you should be aware of. Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent positive topline results from Merck's Phase 3 KEYNOTE-905 trial could enhance the narrative around its strategic investments and new product launches. These developments may bolster Merck's leadership in oncology, potentially driving future revenue as KEYTRUDA applications expand. The efficacy in muscle-invasive bladder cancer strengthens their oncology pipeline, possibly counterbalancing challenges such as declining GARDASIL sales and looming KEYTRUDA exclusivity loss. Over a longer five-year period, Merck's total shareholder return, including dividends, increased by 15.68%, providing broader context compared to its recent quarterly performance. However, over the past year, Merck underperformed the US market, which returned 19.4%, highlighting potential areas for growth despite the positive trial results. The promising trial outcomes may positively impact revenue and earnings forecasts, aligning with analysts' assumptions of a 4.3% annual revenue growth over the next three years. If expectations hold, earnings might reach US$24.3 billion by 2028. Such advancements in the oncology segment could be pivotal given the price target of US$100.41. With the current share price at US$80.03, the price target implies a potential increase of 25.5%, assuming other market conditions remain constant. Evaluate Merck's prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
